Navigation Links
YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
Date:1/26/2010

pan class="xn-person">Andrew Wilks of the JAK 1 / 2 enzymes on the kinome. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has meant met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Miami (PRWEB) May 26, 2015 ... a new stem cells clinic in Buenos Aires, Argentina. ... a renowned critical care specialist. Pastrana has assembled a ... endocrinology and orthopedics in her state-of-the-art Puerto Madero office. ... operate phase I to phase IV clinical studies in ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May ... QIAGEN Clinical Insight ® ... Genvarianten und die Erstellung dazugehöriger Berichte; Vorstellung ...     QIAGEN N.V. (NASDAQ: ... heute die Markteinführung von QIAGEN Clinical Insight ...
(Date:5/26/2015)... 2015   Intrexon Corporation (NYSE: XON ), ... Frost , Ph.D., Senior Vice President and Head of Intrexon,s ... Conference on Wednesday, June 3 rd , at 1:30 p.m. ... York City . About Intrexon Corporation ... Bioindustrial Revolution with Better DNA ™ to create biologically-based ...
(Date:5/26/2015)... FL (PRWEB) May 26, 2015 ... Inc. have announced plans for the company’s first cellular ... 2015, followed by a full day, hands-on stem cell ... by J. Victor Garcia Gimenez, M.D., President of Therapeutic ... the medical community’s increasing interest in regenerative medicine and ...
Breaking Biology Technology:Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3
... and DETROIT, Oct. 22 The Michigan Life,Science ... rapidly,stimulate new business for Michigan companies. (Photo: ... BioPharma Company, LLC and the Michigan Virtual,Medical Device ... exhibit during,the MichBio Expo convention in Lansing, Michigan. ...
... France, October 22 Proteus today,announced the completion ... partner PCAS. PCAS, stake in Proteus now represents ... the increase. Proceeds of this private,placement are to ... PSI and PCAS,BIOSOLUTION businesses. PROTEUS ( http://www.proteus.fr ...
... N.J., Oct. 22 Laser Energetics,Inc. (Pink Sheets: ... into,discussions with several medical and dental instrument suppliers ... their,medical and dental products. LEI,s BrightStar(TM) Alexandrite ... beam delivery system can enhance medical and,dental laser ...
Cached Biology Technology:Virtual Life Science Companies Launch and Tour 2Virtual Life Science Companies Launch and Tour 3PCAS : Tighter Links Between PCAS and Proteus 2Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications 2Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications 3
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Va.The first outcome-based guidelines for interventional treatment ... treatmentwill benefit individuals suffering from brain attacks, ... from the Society of Interventional Radiology and ... and international consensus on the metrics and ...
... Michael Karin is to receive this year,s Charles Rodolphe ... studies on the role of chronic inflammation in the ... in prize money, is considered one of the highest ... place in Zurich this Thursday in the framework of ...
... iron-oxidizing bacteria using electricity instead of iron, an advance that ... one day be used to turn electricity into fuel. The ... , the online open-access journal of the American Society for ... bacteria with a steady supply of electrons that the bacteria ...
Cached Biology News:Medical societies unite on patient-centered measures for nonsurgical stroke interventions 2Brupbacher Prize goes to cancer researcher Michael Karin 2Scientists trick iron-eating bacteria into breathing electrons instead 2